Report cover image

Global Biosimilar Insulin Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 197 Pages
SKU # APRC20360976

Description

Summary

According to APO Research, The global Biosimilar Insulin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Biosimilar Insulin include Biocon, Geropharm, Wockhardt, Gan&Lee, Eli Lilly, United Laboratory, Sanofi and Tonghua Dongbao, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biosimilar Insulin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Biosimilar Insulin, also provides the sales of main regions and countries. Of the upcoming market potential for Biosimilar Insulin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilar Insulin sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biosimilar Insulin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biosimilar Insulin sales, projected growth trends, production technology, application and end-user industry.

Biosimilar Insulin Segment by Company

Biocon
Geropharm
Wockhardt
Gan&Lee
Eli Lilly
United Laboratory
Sanofi
Tonghua Dongbao
Biosimilar Insulin Segment by Type

Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Biosimilar Insulin Segment by Application

Hospital
Retail Pharmacy
Others
Biosimilar Insulin Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Biosimilar Insulin in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilar Insulin sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Biosimilar Insulin Market by Type
1.2.1 Global Biosimilar Insulin Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Biosimilar Insulin Glargine
1.2.3 Biosimilar Insulin Lispro
1.2.4 Other
1.3 Biosimilar Insulin Market by Application
1.3.1 Global Biosimilar Insulin Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Biosimilar Insulin Market Dynamics
2.1 Biosimilar Insulin Industry Trends
2.2 Biosimilar Insulin Industry Drivers
2.3 Biosimilar Insulin Industry Opportunities and Challenges
2.4 Biosimilar Insulin Industry Restraints
3 Global Market Growth Prospects
3.1 Global Biosimilar Insulin Revenue Estimates and Forecasts (2020-2031)
3.2 Global Biosimilar Insulin Revenue by Region
3.2.1 Global Biosimilar Insulin Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Biosimilar Insulin Revenue by Region (2020-2025)
3.2.3 Global Biosimilar Insulin Revenue by Region (2026-2031)
3.2.4 Global Biosimilar Insulin Revenue Market Share by Region (2020-2031)
3.3 Global Biosimilar Insulin Sales Estimates and Forecasts 2020-2031
3.4 Global Biosimilar Insulin Sales by Region
3.4.1 Global Biosimilar Insulin Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Biosimilar Insulin Sales by Region (2020-2025)
3.4.3 Global Biosimilar Insulin Sales by Region (2026-2031)
3.4.4 Global Biosimilar Insulin Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Biosimilar Insulin Revenue by Manufacturers
4.1.1 Global Biosimilar Insulin Revenue by Manufacturers (2020-2025)
4.1.2 Global Biosimilar Insulin Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Biosimilar Insulin Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Biosimilar Insulin Sales by Manufacturers
4.2.1 Global Biosimilar Insulin Sales by Manufacturers (2020-2025)
4.2.2 Global Biosimilar Insulin Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Biosimilar Insulin Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Biosimilar Insulin Sales Price by Manufacturers (2020-2025)
4.4 Global Biosimilar Insulin Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Biosimilar Insulin Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Biosimilar Insulin Manufacturers, Product Type & Application
4.7 Global Biosimilar Insulin Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Biosimilar Insulin Market CR5 and HHI
4.8.2 2024 Biosimilar Insulin Tier 1, Tier 2, and Tier 3
5 Biosimilar Insulin Market by Type
5.1 Global Biosimilar Insulin Revenue by Type
5.1.1 Global Biosimilar Insulin Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Biosimilar Insulin Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Biosimilar Insulin Revenue Market Share by Type (2020-2031)
5.2 Global Biosimilar Insulin Sales by Type
5.2.1 Global Biosimilar Insulin Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Biosimilar Insulin Sales by Type (2020-2031) & (K Units)
5.2.3 Global Biosimilar Insulin Sales Market Share by Type (2020-2031)
5.3 Global Biosimilar Insulin Price by Type
6 Biosimilar Insulin Market by Application
6.1 Global Biosimilar Insulin Revenue by Application
6.1.1 Global Biosimilar Insulin Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Biosimilar Insulin Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Biosimilar Insulin Revenue Market Share by Application (2020-2031)
6.2 Global Biosimilar Insulin Sales by Application
6.2.1 Global Biosimilar Insulin Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Biosimilar Insulin Sales by Application (2020-2031) & (K Units)
6.2.3 Global Biosimilar Insulin Sales Market Share by Application (2020-2031)
6.3 Global Biosimilar Insulin Price by Application
7 Company Profiles
7.1 Biocon
7.1.1 Biocon Comapny Information
7.1.2 Biocon Business Overview
7.1.3 Biocon Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Biocon Biosimilar Insulin Product Portfolio
7.1.5 Biocon Recent Developments
7.2 Geropharm
7.2.1 Geropharm Comapny Information
7.2.2 Geropharm Business Overview
7.2.3 Geropharm Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Geropharm Biosimilar Insulin Product Portfolio
7.2.5 Geropharm Recent Developments
7.3 Wockhardt
7.3.1 Wockhardt Comapny Information
7.3.2 Wockhardt Business Overview
7.3.3 Wockhardt Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Wockhardt Biosimilar Insulin Product Portfolio
7.3.5 Wockhardt Recent Developments
7.4 Gan&Lee
7.4.1 Gan&Lee Comapny Information
7.4.2 Gan&Lee Business Overview
7.4.3 Gan&Lee Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Gan&Lee Biosimilar Insulin Product Portfolio
7.4.5 Gan&Lee Recent Developments
7.5 Eli Lilly
7.5.1 Eli Lilly Comapny Information
7.5.2 Eli Lilly Business Overview
7.5.3 Eli Lilly Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Eli Lilly Biosimilar Insulin Product Portfolio
7.5.5 Eli Lilly Recent Developments
7.6 United Laboratory
7.6.1 United Laboratory Comapny Information
7.6.2 United Laboratory Business Overview
7.6.3 United Laboratory Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 United Laboratory Biosimilar Insulin Product Portfolio
7.6.5 United Laboratory Recent Developments
7.7 Sanofi
7.7.1 Sanofi Comapny Information
7.7.2 Sanofi Business Overview
7.7.3 Sanofi Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Sanofi Biosimilar Insulin Product Portfolio
7.7.5 Sanofi Recent Developments
7.8 Tonghua Dongbao
7.8.1 Tonghua Dongbao Comapny Information
7.8.2 Tonghua Dongbao Business Overview
7.8.3 Tonghua Dongbao Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
7.8.5 Tonghua Dongbao Recent Developments
8 North America
8.1 North America Biosimilar Insulin Market Size by Type
8.1.1 North America Biosimilar Insulin Revenue by Type (2020-2031)
8.1.2 North America Biosimilar Insulin Sales by Type (2020-2031)
8.1.3 North America Biosimilar Insulin Price by Type (2020-2031)
8.2 North America Biosimilar Insulin Market Size by Application
8.2.1 North America Biosimilar Insulin Revenue by Application (2020-2031)
8.2.2 North America Biosimilar Insulin Sales by Application (2020-2031)
8.2.3 North America Biosimilar Insulin Price by Application (2020-2031)
8.3 North America Biosimilar Insulin Market Size by Country
8.3.1 North America Biosimilar Insulin Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Biosimilar Insulin Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Biosimilar Insulin Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Biosimilar Insulin Market Size by Type
9.1.1 Europe Biosimilar Insulin Revenue by Type (2020-2031)
9.1.2 Europe Biosimilar Insulin Sales by Type (2020-2031)
9.1.3 Europe Biosimilar Insulin Price by Type (2020-2031)
9.2 Europe Biosimilar Insulin Market Size by Application
9.2.1 Europe Biosimilar Insulin Revenue by Application (2020-2031)
9.2.2 Europe Biosimilar Insulin Sales by Application (2020-2031)
9.2.3 Europe Biosimilar Insulin Price by Application (2020-2031)
9.3 Europe Biosimilar Insulin Market Size by Country
9.3.1 Europe Biosimilar Insulin Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Biosimilar Insulin Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Biosimilar Insulin Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
9.3.9 Nordic Countries
10 China
10.1 China Biosimilar Insulin Market Size by Type
10.1.1 China Biosimilar Insulin Revenue by Type (2020-2031)
10.1.2 China Biosimilar Insulin Sales by Type (2020-2031)
10.1.3 China Biosimilar Insulin Price by Type (2020-2031)
10.2 China Biosimilar Insulin Market Size by Application
10.2.1 China Biosimilar Insulin Revenue by Application (2020-2031)
10.2.2 China Biosimilar Insulin Sales by Application (2020-2031)
10.2.3 China Biosimilar Insulin Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Biosimilar Insulin Market Size by Type
11.1.1 Asia Biosimilar Insulin Revenue by Type (2020-2031)
11.1.2 Asia Biosimilar Insulin Sales by Type (2020-2031)
11.1.3 Asia Biosimilar Insulin Price by Type (2020-2031)
11.2 Asia Biosimilar Insulin Market Size by Application
11.2.1 Asia Biosimilar Insulin Revenue by Application (2020-2031)
11.2.2 Asia Biosimilar Insulin Sales by Application (2020-2031)
11.2.3 Asia Biosimilar Insulin Price by Application (2020-2031)
11.3 Asia Biosimilar Insulin Market Size by Country
11.3.1 Asia Biosimilar Insulin Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Biosimilar Insulin Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Biosimilar Insulin Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Biosimilar Insulin Market Size by Type
12.1.1 SAMEA Biosimilar Insulin Revenue by Type (2020-2031)
12.1.2 SAMEA Biosimilar Insulin Sales by Type (2020-2031)
12.1.3 SAMEA Biosimilar Insulin Price by Type (2020-2031)
12.2 SAMEA Biosimilar Insulin Market Size by Application
12.2.1 SAMEA Biosimilar Insulin Revenue by Application (2020-2031)
12.2.2 SAMEA Biosimilar Insulin Sales by Application (2020-2031)
12.2.3 SAMEA Biosimilar Insulin Price by Application (2020-2031)
12.3 SAMEA Biosimilar Insulin Market Size by Country
12.3.1 SAMEA Biosimilar Insulin Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Biosimilar Insulin Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Biosimilar Insulin Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Biosimilar Insulin Value Chain Analysis
13.1.1 Biosimilar Insulin Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Biosimilar Insulin Production Mode & Process
13.2 Biosimilar Insulin Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Biosimilar Insulin Distributors
13.2.3 Biosimilar Insulin Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.